Choose License Type
The global virus filtration market was valued at USD 3.02 billion in 2019. One of the main factors leading to development is the growing incidence of chronic diseases. The need for biologics is expected to be driven by an increased incidence of chronic diseases, including cancer, diabetes, and autoimmune disorders. Around 14.1 million new cases of cancer were diagnosed worldwide in 2012, according to the International Organization for Research on Cancer, and this figure is expected to reach 21.7 million by 2030. Thus, there is an increasing market for therapeutic biologics, which subsequently fuels the demand for R&D and manufacturing applications for virus filtration devices.
Another key factor expected to fuel the demand is compliance with drug development and production regulatory mechanisms such as current good manufacturing practise (cGMP) regulations. Virus protection of these products is maintained by producers by multiple quality management initiatives such as raw materials inspection and quality control, certification and enforcement of successful virus clearance t Thus, for production and R&D activities, the market for these goods is very strong. CROs partner with biotechnology and biopharmaceutical firms to produce experimental medicines and treatments, which are also projected to help the expansion of the market.
Key segments of the global virus filtration market
Product Overview, 2018-2028 (USD Billion)
Technology Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Reasons for the study
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global virus filtration market
The protection of viruses in biotech and plasma-derived therapeutics is assured by complementary development and quality management steps, including control and inspection of raw materials, validation and application of appropriate virus clearance technologies, and monitoring of the existence of viruses in the finished product. A typical unit process in the manufacture of biological products is virus filtration, which is considered a durable and efficient virus clearance technology.
In order to preserve viral particles, virus filtration employs a membrane barrier. It is a form of removal depending on size that uses a specially engineered polymeric membrane to preserve particles of viruses on the surface and inside the membrane pores. Usually, the log reduction value (LRV) and the throughput are the critical efficiency parameters.
The global market is segmented on the basis of product, technology, application. The product segment is further broken down to consumables, instruments, and services. The technology segment is further broken down into filtration and chromatography. The application segment is broken down into biologicals, medical devices, water purification, air purification.
In 2019, consumables dominated the global market on account f its highest consumption for viral filtration techniques. Regular use across all the applications is the major factor for segment growth.
It is expected that the services segment will display the highest CAGR during the study period. This is attributed to expanded biotechnology firms' outsourcing of R&D and drug production facilities from CROs. In addition, CROs partner with biotechnology and biopharmaceutical firms to create innovative medicines and treatments that are projected to sustain development in the segment.
On the basis of region, the global market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East and Africa. As of 2018, North America accounted for the dominant share compared to other regional markets, and is projected to retain its domination throughout the forecast period. The presence of large scale suppliers, well-established healthcare facilities, and high recognition among the surgeons culminated in this region's growing acceptance of the process. Because of the strong demand for novel virus filtration products for research and the growth and manufacture of biologics, Europe was the second largest market. Furthermore, the international sector is projected to be powered by highly developed healthcare infrastructure and large-scale developments in R&D, mainly in Germany, the UK and France.
Key players in the market include Merck KGaA, Danaher, Thermo Fisher Scientific Inc, GE Healthcare, Charles River Laboratories International, Inc, WuXi PharmaTech, and many more. To gain revenue share in the industry, leading producers are engaged in mergers and acquisitions, strategic partnerships, and novel product growth. Mergers and acquisitions assist companies in growing their current market and global presence. For example, Danaher Corporation completed the acquisition of Pall Corporation, a leading supplier of products for virus filtration, in August 2015.
The global virus filtration market was valued at USD 3.02 billion in 2019. One of the main factors leading to development is the growing incidence of chronic diseases. The need for biologics is expected to be driven by an increased incidence of chronic diseases, including cancer, diabetes, and autoimmune disorders. Around 14.1 million new cases of cancer were diagnosed worldwide in 2012, according to the International Organization for Research on Cancer, and this figure is expected to reach 21.7 million by 2030. Thus, there is an increasing market for therapeutic biologics, which subsequently fuels the demand for R&D and manufacturing applications for virus filtration devices.
Another key factor expected to fuel the demand is compliance with drug development and production regulatory mechanisms such as current good manufacturing practise (cGMP) regulations. Virus protection of these products is maintained by producers by multiple quality management initiatives such as raw materials inspection and quality control, certification and enforcement of successful virus clearance t Thus, for production and R&D activities, the market for these goods is very strong. CROs partner with biotechnology and biopharmaceutical firms to produce experimental medicines and treatments, which are also projected to help the expansion of the market.
Key segments of the global virus filtration market
Product Overview, 2018-2028 (USD Billion)
Technology Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Reasons for the study
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global virus filtration market
1. Introduction
1.1. Introduction
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. Porter’s Five Forces Analysis
3.4. COVID-19 impact analysis
4. Virus Filtration Market by Product, 2018-2028 (USD Million)
4.1. Consumables
4.2. Instruments
4.3. Services
5. Virus Filtration Market by Technology, 2018-2028 (USD Million)
5.1. Filtration
5.2. Chromatography
6. Virus Filtration Market by End use, 2018-2028 (USD Million)
6.1. Biologicals
6.2. Medical devices
6.3. Water purification
6.4. Air purification
7. Virus Filtration Market by Region 2018-2028 (USD Million)
7.1. North America
7.1.1. U.S.
7.1.2. Canada
7.2. Europe
7.2.1. UK
7.2.2. Germany
7.2.3. France
7.2.4. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Rest of APAC
7.4. Latin America
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Middle East & Africa
8. Competitive Landscape
8.1. Company Ranking
8.2. Market Share Analysis
8.3. Strategic Initiatives
8.3.1. Mergers & Acquisitions
8.3.2. New Type Launch
8.3.3. Investments
8.3.4. Expansion
8.3.5. Others
9. Company Profiles
9.1. Merck KGaA
9.1.1. Overview
9.1.2. Types Portfolio
9.1.3. Recent Initiatives
9.1.4. Company Financials
9.2. Danaher
9.3. Sartorius AG
9.4. Thermo Fisher Scientific Inc
9.5. GE Healthcare
9.6. Charles River Laboratories International, Inc
9.7. Asahi Kasei Medical Co., Ltd
9.8. WuXi PharmaTech Inc
9.9. Lonza Group Ltd.
9.10. Clean Cells Inc.
10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Primary Interview Summary
10.2. Questionnaire
10.3. Related Reports
10.3.1. Published
10.3.2. Upcoming